detd-35

DETD-35 is a semi-synthetic derivative of deoxyelephantopin, a plant-derived sesquiterpene lactone originally identified for anti-inflammatory and anti-tumor properties[1][3][5][7][9]. DETD-35 shows potent anti-proliferative and pro-apoptotic activity against cancer cells, including triple-negative breast cancer (TNBC) and BRAFV600E-mutant melanoma, as well as models of acquired resistance to vemurafenib[1][3][5]. The drug acts primarily by inducing oxidative stress, disrupting mitochondrial integrity, escalating cytosolic calcium, and altering exosomal protein profiles released from tumor cells. Mechanistically, DETD-35 overcomes acquired vemurafenib resistance through inhibition of key oncogenic signaling pathways—MEK-ERK, Akt, and STAT3—leading to apoptosis[3][5][9]. It has demonstrated superior efficacy to its parent compound and shows synergistically enhanced effects when combined with vemurafenib in preclinical models[3][5][7]. No cytotoxicity to normal cells has been reported at effective concentrations[3][5].

Brand names

DETD-35DETD35DETD 35

Other names

DETD-35DETD35DETD 35